Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients
- 17 February 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Virchows Archiv
- Vol. 462 (3), 289-296
- https://doi.org/10.1007/s00428-013-1382-8
Abstract
Difference in prognosis between grade 3 endometrioid carcinoma (G3EC) of the endometrium and uterine serous carcinoma (USC) is controversial. In this study, we further evaluated the difference in prognosis, if any, between G3EC (n = 61) and USC (n = 47) on a total of 565 patients with endometrial cancer. In addition, meta-analysis was performed using data from seven previous publications (n = 8,637) and from the Asan Medical Center (n = 108). Regarding the cases from our institution, USC tended to occur in older patients (≥65 years) than G3EC (P = 0.011). Deep myometrial invasion (more than or equal to half) was more frequently identified in G3EC (36/61, 59.0 %) than in USC (17/47, 36.2 %) (P = 0.021). Between patients with early stage G3EC and USC (stages I and II), there were no significant differences in any clinicopathological parameter, but there was a significant difference in overall survival (P = 0.017) that was not found in advanced stage (P = 0.588). USC was an independent prognostic factor for poor overall survival (hazard ratio, 6.125; P = 0.030) in early stage patients. In the meta-analysis on 5-year survival in patients with early stage cancers, which also included our study results, a higher relative risk (1.92, 95 % CI 1.62–2.27) was demonstrated in USC than in G3EC (P < 0.001). In conclusion, our study reveals that USC is associated with a poorer prognosis compared with G3EC, only in patients with early stage carcinoma, suggesting that different treatment strategies should be considered according to the histologic type in order to improve treatment outcome.Keywords
This publication has 27 references indexed in Scilit:
- The dualistic model of endometrial cancer: The challenge of classifying grade 3 endometrioid carcinomaGynecologic Oncology, 2012
- Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometriumEuropean Journal of Surgical Oncology, 2010
- Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical studyVirchows Archiv, 2010
- Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancersBritish Journal of Cancer, 2006
- Endometrial cancerThe Lancet, 2005
- Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometriumGynecologic Oncology, 2004
- Uterine serous and grade 3 endometrioid carcinomasCancer, 2004
- The Outcome of Stage I–II Clinically and Surgically Staged Papillary Serous and Clear Cell Endometrial Cancers When Compared with Endometrioid CarcinomaGynecologic Oncology, 2000
- Recent advances in the histopathology and molecular pathology of carcinoma of the endometriumHistopathology, 1998
- Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiationHuman Pathology, 1998